Benitec Biopharma Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial

Reuters01-11

<a href="https://laohu8.com/S/BNTC">Benitec Biopharma</a> Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial

Benitec Biopharma Inc. announced positive long-term results from its Phase 1b/2a clinical trial evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dystrophy (OPMD). The company reported that the first patient in Cohort 1 completed a 24-month post-treatment assessment, showing continued improvements in post-swallow pharyngeal residue and total dysphagic symptom burden compared to earlier timepoints. Additionally, all four patients in Cohort 1 completed the 12-month statistical follow-up period and met the pre-specified criteria for response to BB-301, demonstrating a durable response. Benitec Biopharma plans to engage with the U.S. Food and Drug Administration in mid-2026 to confirm the pivotal study design and will continue to present interim clinical results at future medical conferences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623395) on January 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602155969?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-11 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602155969","market":"fut","top_or_hot":-1,"title":"Benitec Biopharma Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BNTC\">Benitec Biopharma</a> Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BLT.AU\">Benitec Biopharma</a> Inc. announced positive long-term results from its Phase 1b/2a clinical trial evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dystrophy (OPMD). The company reported that the first patient in Cohort 1 completed a 24-month post-treatment assessment, showing continued improvements in post-swallow pharyngeal residue and total dysphagic symptom burden compared to earlier timepoints. Additionally, all four patients in Cohort 1 completed the 12-month statistical follow-up period and met the pre-specified criteria for response to BB-301, demonstrating a durable response. Benitec Biopharma plans to engage with the U.S. Food and Drug Administration in mid-2026 to confirm the pivotal study design and will continue to present interim clinical results at future medical conferences.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623395) on January 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Benitec Biopharma Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBenitec Biopharma Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-11 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BNTC\">Benitec Biopharma</a> Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BLT.AU\">Benitec Biopharma</a> Inc. announced positive long-term results from its Phase 1b/2a clinical trial evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dystrophy (OPMD). The company reported that the first patient in Cohort 1 completed a 24-month post-treatment assessment, showing continued improvements in post-swallow pharyngeal residue and total dysphagic symptom burden compared to earlier timepoints. Additionally, all four patients in Cohort 1 completed the 12-month statistical follow-up period and met the pre-specified criteria for response to BB-301, demonstrating a durable response. Benitec Biopharma plans to engage with the U.S. Food and Drug Administration in mid-2026 to confirm the pivotal study design and will continue to present interim clinical results at future medical conferences.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623395) on January 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL3wndQx:1","article_id":"2602155969","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602155969","pubTimestamp":1768136435,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Benitec Biopharma Inc. announced positive long-term results from its Phase 1b/2a clinical trial evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dystrophy . The company reported that the first patient in Cohort 1 completed a 24-month post-treatment assessment, showing continued improvements in post-swallow pharyngeal residue and total dysphagic symptom burden compared to earlier timepoints. Additionally, all four patients in Cohort 1 completed the 12-month statistical follow-up period and met the pre-specified criteria for response to BB-301, demonstrating a durable response. Benitec Biopharma plans to engage with the U.S. Food and Drug Administration in mid-2026 to confirm the pivotal study design and will continue to present interim clinical results at future medical conferences.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BNTC":"Benitec Biopharma Limited","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","BK4112":"金融交易所和数据","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Benitec Biopharma报告BB-301在OPMD 1b/2a期试验中的持久疗效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTC":0.9,"NDAQ":0.9},"content_text":"Benitec Biopharma Reports Durable Efficacy for BB-301 in OPMD Phase 1b/2a Trial\n    \n\nBenitec Biopharma Inc. announced positive long-term results from its Phase 1b/2a clinical trial evaluating BB-301 for the treatment of dysphagia in oculopharyngeal muscular dystrophy (OPMD). The company reported that the first patient in Cohort 1 completed a 24-month post-treatment assessment, showing continued improvements in post-swallow pharyngeal residue and total dysphagic symptom burden compared to earlier timepoints. Additionally, all four patients in Cohort 1 completed the 12-month statistical follow-up period and met the pre-specified criteria for response to BB-301, demonstrating a durable response. Benitec Biopharma plans to engage with the U.S. Food and Drug Administration in mid-2026 to confirm the pivotal study design and will continue to present interim clinical results at future medical conferences.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623395) on January 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602155969","isCrawlerRequest":true}